Nicole Sweeny, the Chief Commercial Officer of $KALV, sold 1,480 shares of the company on 08-25-2025 for an estimated $19,861. We received data on the trade from a recent SEC filing. This was a sale of approximately 4.4% of their shares of this class of stock. Following this trade, they now own 32,291 shares of this class of $KALV stock.
$KALV Insider Trading Activity
$KALV insiders have traded $KALV stock on the open market 23 times in the past 6 months. Of those trades, 1 have been purchases and 22 have been sales.
Here’s a breakdown of recent trading of $KALV stock by insiders over the last 6 months:
- BENJAMIN L PALLEIKO (CHIEF EXECUTIVE OFFICER) has made 0 purchases and 7 sales selling 75,973 shares for an estimated $1,067,940.
- CHRISTOPHER YEA (CHIEF DEVELOPMENT OFFICER) has made 0 purchases and 7 sales selling 44,058 shares for an estimated $647,173.
- HEALTHCARE CAPITAL PARTNERS III, L.P. VENROCK purchased 25,000 shares for an estimated $235,500
- PAUL K. AUDHYA (CHIEF MEDICAL OFFICER) has made 0 purchases and 6 sales selling 15,828 shares for an estimated $198,087.
- NICOLE SWEENY (Chief Commercial Officer) has made 0 purchases and 2 sales selling 3,344 shares for an estimated $44,508.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$KALV Hedge Fund Activity
We have seen 84 institutional investors add shares of $KALV stock to their portfolio, and 63 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AMERIPRISE FINANCIAL INC added 905,053 shares (+2258.6%) to their portfolio in Q2 2025, for an estimated $10,231,624
- GREAT POINT PARTNERS LLC removed 691,197 shares (-68.1%) from their portfolio in Q2 2025, for an estimated $7,813,982
- DIMENSIONAL FUND ADVISORS LP removed 472,784 shares (-73.2%) from their portfolio in Q2 2025, for an estimated $5,344,823
- SCHONFELD STRATEGIC ADVISORS LLC removed 436,464 shares (-75.0%) from their portfolio in Q2 2025, for an estimated $4,934,225
- ALLOSTERY INVESTMENTS LP removed 418,302 shares (-91.3%) from their portfolio in Q2 2025, for an estimated $4,728,904
- JPMORGAN CHASE & CO removed 379,286 shares (-94.2%) from their portfolio in Q2 2025, for an estimated $4,287,828
- JEFFERIES FINANCIAL GROUP INC. removed 375,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $4,239,375
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$KALV Analyst Ratings
Wall Street analysts have issued reports on $KALV in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 07/11/2025
- Needham issued a "Buy" rating on 04/08/2025
- Citizens Capital Markets issued a "Market Outperform" rating on 03/26/2025
- Jones Trading issued a "Buy" rating on 03/26/2025
To track analyst ratings and price targets for $KALV, check out Quiver Quantitative's $KALV forecast page.
$KALV Price Targets
Multiple analysts have issued price targets for $KALV recently. We have seen 6 analysts offer price targets for $KALV in the last 6 months, with a median target of $27.0.
Here are some recent targets:
- Andrew Fein from HC Wainwright & Co. set a target price of $27.0 on 07/11/2025
- Jonathan Wolleben from JMP Securities set a target price of $27.0 on 07/08/2025
- Joseph Schwartz from Leerink Partners set a target price of $20.0 on 07/07/2025
- Serge Belanger from Needham set a target price of $28.0 on 04/08/2025
- Jonathan Wolleben from Citizens Capital Markets set a target price of $19.0 on 03/26/2025
- Debanjana Chatterjee from Jones Trading set a target price of $30.0 on 03/26/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
